Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma — Stella

Recruiting

Back to Maintenance Treatment of Peripheral T-cell Lymphoma trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai

Key details

Phase

Large-scale testing

Sponsor

Fudan University

Enrollment target

~136 participants

Started

March 2026

Primary completion

December 2028

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov